Evaluation of Adenosine Deaminase Level in Reactional and Non-Reactional Leprosy

Thesis
Submitted for Partial Fulfillment
of Master Degree in
Dermatology and Venereology

By Nahla Kamal Abo El Yazid Darwish M.B.B.CH

Supervisor

Prof. Dr / Hoda Ahmed Moneib

Prof. of Dermatology and Venereology Faculty of Medicine Ain Shams University

Dr / Sahar El Sayed Youssef

Assistant Prof. of Dermatology and Venereology
Faculty of Medicine
Ain Shams University

Dr / Ghada Ahmed Abd El Aleem

Lecturer of Biochemistry Faculty of Medicine Tanta University

Faculty of Medicine Ain Shams University 2010

نزیم دنوزین دی مینیز فی غیر التفاعلی

توطئه مقدمة الى كلية الطبع جامعة عين شمس للحصول على درجة الماجستير في الجادية والتناسلية

الطبيبة/ نملة كمال أبو اليزيد درويش

الأستاذة الدكتورة / مدى أحمد منيب

أستاذ الأمراض الجلدية والتناسلية بكلية الطب جامعة عين شمس

الدكتورة / سعر السيد يوسف

أستاذ مساعد الأمراض الجلدية و التناسلية بكلية الطب جامعة عين شمس

الدكتورة/ غادة أحمد عبدالعليم

مدرس الكيمياء الحيوية بكلية الطب حامعة طنطا

> جامعة عين شمس كلية الطب 2010

Contents

Topic	page
Contents	i
List of figures	ii
List of tables	iii
List of abbreviations	iv,v
Introduction & Aim of work	1-3
Review of literature -A general view on leprosy -Reaction, nerve and system involvement -Investigations -Adenosine deaminase	4-82 4-40 41-56 57-65 66-82
Subjects and methods	83-94
Results	95-106
Discussion	107-111
Summary and conclusion	113-116
References	117-142
Arabic summary	أ_ب_ج_د

İ

List of Figures

Figure	Subject	Page
(1)	Pevalence rate of leprosy in world.	9
(2)	Numbers of new cases in Egypt up to 2007.	10
(3)	Morphology of M.leprae.	14
(4)	Infrared image of face.	15
(5)	A multibacillary leprosy patient.	15
(6)	Immunopathologic spectrum of leprosy.	24
(7)	Histopathology of histoid leprosy.	29
(8)	Mitsuda reaction and leprosy.	34
(9)	Bipolar distribution of leprosy.	36
(10)	Bipolarity of macrophage in leprosy.	37
(11)	Immune reaction in lepromatous leprosy	38
(12)	Immune reaction in tuberculoid leprosy.	39
(13)	Model of infection of nerve by M. leprae.	49
(14)	Electron micrographs of M. leprae-infected rat.	52
(15)	MDT anti-leprosy.	65
(16)	Reaction of adenosine deaminase.	68
(17)	Number of patients in different types of leprosy.	96
(18)	Demographic results in all patients and controls.	97
(19)	ADA level in all patients compared to controls.	98
(20)	ADA level in each group compared to controls.	99
(21)	ADA level in lepromatous leprosy compared to tuberculoid leprosy.	100
(22)	ADA level in pucibacillary leprosy compared to multibacillary leprosy and controls.	101
(23)	ADA level in active leprosy compared to inactive leprosy and control group.	102
(24)	Comparison of serum ADA level in both types of reaction.	103

List of tables

Table	Subject	Page
(1)	Basic statistic of leprosy in Egypt.	10
(2)	Basic statistic of leprosy in Mediternean region.	11
(3)	Clinical finding of types of leprosy.	30
(4)	Classification of leprosy.	31,32
(5)	Comparison between type 1 and type 2 leprosy reaction.	45
(6)	Systemic changes in leprosy.	56
(7)	The assay procedure 1.	89
(8)	The assay procedure 2.	90
(9)	Clinical finding of each subject.	92,93, 94
(10)	Distribution of patients in each group.	96
(11)	Demographic results in all patients and controls.	97
(12)	ADA level in all patients compared to controls.	98
(13)	ADA level in each group compared to controls.	99
(14)	ADA level in lepromatous compared to tuberculoid leprosy.	100
(15)	ADA level in pucibacillary leprosy compared to multibacillary leprosy and controls.	101
(16)	ADA level in active leprosy compared to inactive leprosy and controls.	102
(17)	Comparison of serum ADA level in both types of reaction.	103
(18)	Age, sex, ADA, slit skin smaer and diagnosis	104

Abbreviation

- **ADA**: Adenosine deaminase.
- **ADP:** Adenosine diphosphate.
- **AFB**: Acid fast bacillus.
- AIDS: Acquired immune deficiency syndrome
- ATL: Acute T cell leukemia.
- **ATP**: Adenosine triphophatse.
- **APCs**: Antigen presenting cells.
- **BBL**: Borderline borderline leprosy.
- BCG: Bacillus Calmette-Guérin.
- **BL**: Borderline leprosy.
- **BT**: Borderline tuberculoid.
- **BI:** Bacteriological index.
- **bp**:base pairs.
- **C**: Cytosine.
- **CD:** Cluster of differentiation.
- **CMI**: Cell-mediated immunity.
- **CRF:** Case report form.
- **CXCL10:** Chemokine (C-X-C motif) ligand 10.
- DNA: Deoxyribonucleic acid.
- **EC number:** Enzyme Commission number.
- **ENL:** Erythema nodosum leprosum.
- **G**: Guanine.
- **HIV:** Human immunodeficiency virus
- HLA: Human leucocytic antigen.
- **HTLV**-1: Human T cell virus-1.
- **IL:** Interleukin.
- **IFN:** Interferon.
- **iNOS**: inducible nitric oxide synthase.
- **ISBN:** International Standard Book Number.
- kD: kilodalton.
- **Lepromin A**: Lepromin armadillo.
- **Lepromin H**: Lepromin human.
- **L-ADA:** Lymphocyte adenosine deaminase.

- LL: Lepromatous leprosy.
- Lrtl: Low resistant tuberculoid leprosy.
- M. leprae: Mycobacterium leprae.
- **Mal**: Maculoanesthetic.
- **Mb**: Megabases (million of base pairs).
- **MB:** Multibacillary.
- **MDT:** Multidrug therapy.
- MHC: Major histocompatibility complex.
- MI: Morphological index.
- MoAb: Monoclonal antibodies.
- **mRNA**: Messenger ribonucleic acid.
- NASBA: Nucleic acid sequence basd amplification.
- NAPCs: New antigen presenting cells.
- **PB:** Paucibacillary leprosy.
- **PCR**: Polymerase chain reaction.
- **PGDF:** Platelet-derived growth factor.
- **PGL**-1: Phenolic glycolipid-1.
- **PNL**: Pure neuritic leprosy.
- **qRT –PCR** :quantitative reverse transcriptase polymerase chain reaction.
- RL:Reactional leprosy
- **rRNA**: ribosomal ribonucleic acid.
- SCs: Schwann cells.
- **SCID**: Severe combined immunodeficiency.
- **sLL**:subpolar lepromatous.
- **TB:** Tuberculosis.
- **Th:** T-helper cell.
- **TLR**: Toll-like receptor.
- **Tm**: macular tuberculoid leprosy.
- TNF-α: Tumor necrosis factor alpha.
- **Tt:** subpolar tuberculoid.
- **TT:** Tuberculoid leprosy.
- WHO: World Health Organization.

Acknowledgments

Thanks to God first and foremost. I feel always indebted to God, the most kind and the most merciful.

I would like to express my gratefulness and respect to **Prof. Dr. Hoda Ahmed Moneib,** Professor of Dermatology and Venereology, Ain Shams University, for her moral and scientific support and for giving me the honor of working under her supervision and valuable guidance.

I would like to express my gratitude and appreciation to **Dr. Sahar El Sayed Youssef,** Assiatant Professor of Dermatology and Venereology, Ain Shams University, for her sincerely scientific and moral help.

Special thanks and deepest gratitude to **Dr. Ghada**Ahmed Abd El Aleem, Lecturer of Biochemistry, Tanta

University, for her constructive and instructive comments and valuable suggestions.

They encouraged me all the time for a better performance. Without their generous help, this work would not have been accomplished in its present picture.

Words can not describe my gratefulness and gratitude to the greatest mother, father and my siblings who provided me with every mean of support throughout my life.



Acknowledgments

Thanks to God first and foremost. I feel always indebted to God, the most kind and the most merciful.

I would like to express my gratefulness and respect to **Prof. Dr.** Hoda Ahmed Moneib, Professor of Dermatology and Venereology, Ain Shams University, for her moral and scientific support and for giving me the honor of working under her supervision and valuable guidance.

I would like to express my gratitude and appreciation to **Dr.** Sahar El Sayed Youssef, Assiatant Professor of Dermatology and Venereology, Ain Shams University, for her sincerely scientific and moral help.

Special thanks and deepest gratitude to **Dr. Ghada Ahmed Abd El Aleem**, Lecturer of Biochemistry, Tanta University, for her constructive and instructive comments and valuable suggestions.

They encouraged me all the time for a better performance. Without their generous help, this work would not have been accomplished in its present picture.

Words can not describe my gratefulness and gratitude to the greatest mother, father and my siblings who provided me with every mean of support throughout my life.



Acknowledgments

Thanks to God first and foremost. I feel always indebted to God, the most kind and the most merciful.

I would like to express my gratefulness and respect to **Prof. Dr. Hoda Ahmed Moneib,** Professor of Dermatology and Venereology, Ain Shams University, for her moral and scientific support and for giving me the honor of working under her supervision and valuable guidance.


I would like to express my gratitude and appreciation to **Dr. Sahar El Sayed Youssef,** Assiatant Professor of Dermatology and Venereology, Ain Shams University, for her sincerely scientific and moral help.

Special thanks and deepest gratitude to **Dr. Ghada**Ahmed Abd El Aleem, Lecturer of Biochemistry, Tanta

University, for her constructive and instructive comments and valuable suggestions.

They encouraged me all the time for a better performance. Without their generous help, this work would not have been accomplished in its present picture.

Words can not describe my gratefulness and gratitude to the greatest mother, father and my siblings who provided me with every mean of support throughout my life.



Introduction

Leprosy, or Hansen's disease, is a chronic infectious disease caused by the bacterium Mycobacterium leprae (M.Leprae) (*Sasaki et al.*, 2001). Leprosy is primarily a granulomatous disease of the peripheral nerves and mucosa of the upper respiratory tract; skin lesions are the primary external symptom (*Stefani et al.*, 2009). Leprosy is still a significant public health problem. Disease prevalence has fallen due to introduction of multidrug therapy (MDT) (*World Health Organisation*, 2010).

Reactions are a characteristic and clinically important aspect of Hansen's disease. Fifty percent will experience reaction after the institution of MDT. In addition to antibiotic therapy, intercurrent infection, vaccination, pregnancy, vitamin A, iodides and bromide may trigger reactions. Reactions can be severe and are an important cause of permanent nerve damage in leprosy patients. Reactional state is frequently abrupt in their appearance which changes slowly. It is therefore a common reason for patients to seek consultation (*James et al.*, 2006).

There is no quick and easy method for identification of M.Leprae in clinical specimens, diagnosis of leprosy is based primarily on clinical ground. M.Leprae cannot be cultured in the laboratory (*Clark-Curtiss et al.*, 1985). Diagnosis is often confirmed by microscopic observation of acid–fast bacilli (AFB) in fresh slit skin smears. Since microscopy requires an estimated 10,000 organisms/g of tissue, AFB staining is positive for most patients with multibacillary, but is frequently negative in paucibacillary cases. Serological testing is not useful for diagnosis as it does not detect most paucibacillary cases (*Roche et al.*, 1993). A cutaneous nerve biopsy is frequently required to establish the diagnosis of pure neural

leprosy (*Jacob and Mathai*, 1988). So a sensitive and specific method for detection of M. leprae might simplify the diagnosis of leprosy. Recently developed molecular techniques have the potential for more sensitive detection of M.Leprae but they are expensive (*De-Wit et al.*, 1993; *Pham et al.*, 2009).

There is a need for a method not only less expensive but also facilitates detection of the activity of microorganisms especially in reactional leprosy. Adenosine deaminase (ADA), an enzyme of purine metabolism in part regulates the lymphocyte metabolism and is also important for lymphocytic differentiation and growth (*Fischer et al.*, 1976).

ADA is present in T-lymphocytes and varies according to cellular differentiation. Its activity appears to be necessary for an effective immune response as shown by many studies like in combined immunodeficiency disease and in typhoid fever. Besides this, increased activity of serum ADA has also been demonstrated in tubercular pleural effusion and active tuberculosis (*Bhargava et al, 1990; Ahmed et al., 2008*).

An increased activity of serum ADA has also been demonstrated in leprosy patients. The cellular immune aberration seen in the different types of leprosy may be due to abnormal proliferation of lymphocytes in response to M. leprae (*Suri Babu et al.*, 1990). There was also increase in serum ADA level in multibacillary leprosy patients as compared to paucibacillary leprosy patients. Furthermore, this was increased in patients of leprosy with reaction. This may be because of increased lymphoreticular activity during the reactional phase. So ADA can be applied as a marker of activity of leprosy (*Nigam et al.*, 2005).

AIM OF WORK

The aim of this study is to evaluate ADA as a marker of activity of leprosy in general and in lepra reaction in particular.

Leprosy

Synonyms:

Hansen's disease, hanseniasis, elephantiasis grecorum and names in local languages in endemic areas are different names of leprosy (*Lockwood*, 2004).

Leprosy definition:

Leprosy is chronic granulomatous disease of the skin, mucosa of the upper respiratory tract and peripheral nerves caused by M. leprae (*Stefani et al.*, 2009).

Etymology:

The word leprosy is derived from the Greek lepi (), meaning scales on a fish and lepein, to peel (*Barnhart*, 1995).

History:

Leprosy was described in the Hindu religious book Atharva-veda. The Cambridge Encyclopedia of Human Pale pathology holds that: "The Sushruta Samhita from India describes the condition well and even offers therapeutic suggestions as early as about 600 B.C." (*Aufderheide et al.*, 1998).

Chinese text on bamboo slip in the third century B.C., not only described the destruction of the "pillar of the nose", but also the "swelling of the eyebrows, loss of hair, absorption of nasal cartilage, difficult and hoarse respiration, as well as anesthesia. In the West, the earliest description of leprosy was made by the Roman (25 B.C. – 37 A.D.), called leprosy "elephantiasis". In the Muslim world, the Persian polymath Avicenna (980–1037 A.D.) was the first outside China to describe the destruction of the nasal septum in those suffering from leprosy (*Mc Leod et al., 1981*).